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ABSTRACT
Introduction: Sarcoidosis is a systemic
granulomatous disease of unknown cause. The
management of sarcoidosis remains problematic.
Systemic and topical corticosteroids are the
mainstay of therapy but may cause unacceptable
side effects. Biologic therapies, such as infliximab,
have recentlybeenproposed asanother treatment
option for cutaneous sarcoidosis.
Case Report: The authors describe three
patients who were diagnosed with cutaneous
sarcoidosis with systemic involvement. All of
the patients were refractory to conventional
therapies but responded to infliximab therapy.
Conclusion: Infliximab is an alternative
medication for refractory sarcoidosis that has a
relatively benign side-effect profile. However,
definite indications, dosage, interval, and
duration of treatment for cutaneous sarcoidosis
are not firmly established.
Keywords: Biologic; Cutaneous; Infliximab;
Sarcoidosis; Therapy; Treatment; Tumor
necrosis factor inhibitor
INTRODUCTION
Sarcoidosis is a multisystemic granulomatous
disease of unknown origin. Cutaneous
manifestations occur in approximately one
quarter of sarcoid patients, and these lesions
may present at the onset of the disease or
following other systemic involvement [1]. The
management of sarcoidosis remains a
significant therapeutic challenge. Systemic and
topical corticosteroids are popularly used
treatment methods in cutaneous sarcoidosis
but are a poor long-term management strategy
given the range of side effects. Treatment with
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biologic agents has recently been proposed as
another treatment option for cutaneous
sarcoidosis [2–5]. In the past decade, a number
of case series has shown that infliximab is an
effective and well-tolerated management
strategy for this condition [3–26]. The authors
report three cases of cutaneous sarcoidosis that
were refractory to standard therapy but
responded to infliximab treatment. The
authors also review the literature concerning
the treatment of sarcoidosis with infliximab.
CASE REPORT
Case 1
A 43-year-old African American man with a
history of pulmonary sarcoidosis was seen in
the authors’ clinic in December 2007 because of
a 4-month history of lesions on the patient’s
cheeks and legs. The patient was treated
with increasing doses of prednisone,
hydroxychloroquine, and intralesional
corticosteroids without improvement. As a
result of a combination of lack of efficacy and
intolerable side effects of these medications, the
patient was switched to infliximab 5 mg/kg
intravenously on weeks 0, 2, and 6, and then
every 8 weeks in November 2008. After three
infusions, the patient showed significant
improvement of skin lesions, and prednisone
was tapered back to 2.5 mg every other day.
However, after 6 months of infusions, the
patient began to experience some flaring of
cutaneous lesions. Methotrexate 7.5 mg weekly
was added in May 2009 in addition to
infliximab in an effort to improve further the
patient’s cutaneous lesions. In addition,
infliximab was increased to 5 mg/kg every
7 weeks, and shortly thereafter was increased again
to 7.5 mg/kg every 7 weeks in November 2009
for flares near the time of infusion. The patient’s
cutaneous sarcoidosis was stable on this dose of
methotrexate and infliximab for 9 months. In
June 2011, the dosage again had to be increased
to 10 mg/kg every 5 weeks due to flaring of
lesions before infusions, which was able to
control the disease better (Table 1).
Case 2
A 53-year-old African American woman with a
history of pulmonary sarcoidosis for 15 years
was referred to the authors’ clinic on April 2002
for management of 5 years of cutaneous
sarcoidosis lesions. The patient’s cutaneous
lesions were primarily involving the nasal ala
and bilateral cheeks in a distribution consistent
with lupus pernio. The patient was treated
with oral prednisone, hydroxychloroquine,
methotrexate, minocycline, topical tacrolimus,
and topical imiquimod at various points and
only showed moderate improvement with
systemic steroids. The patient was started on
mycophenolate mofetil 500 mg twice a day in
December 2003, increasing to as high as
4 g/day. However, the patient continued to
experience refractory lesions at this dose
(Fig. 1), with multiple erythematous to
violaceous papules and plaques on the
patient’s right cheek, tip of the nose, and
corner of the mouth. Infliximab 7.5 mg/kg was
started in May 2004 at weeks 0, 2, and 6, and
then every 8 weeks, and the dosage of
mycophenolate mofetil was decreased to 1 g
twice a day and prednisone 10 mg/day.
Five months after initiating infliximab, the
patient’s skin lesions showed moderate
flattening without any adverse side effects.
Mycophenolate mofetil was slowly tapered in
October 2007 and was stopped in May 2008.
Prednisone was tapered over the course
of 6 weeks and ended in November 2011.
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Table 1 Patient demographic data
Case 1 Case 2 Case 3












Nodular lesions on face, eyelids,
and earlobes
Multiple erythematous to
violaceous papules on eyelids,
right cheek, tip of nose, and
corner of mouth
Multiple erythematous annular
plaques around eyes, nose,
perioral area, neck, arm, back
and knees
Histopathology From right cheek:
granulomatous inﬂammatory
inﬁltrate (lymphocytes,
histiocytes, and giant cells)









































diarrhea and abdominal pain
Methotrexate-induced








2 years 18 years 8 years
Treatments used
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Fig. 1 The clinical manifestations of case 2 before
initiating inﬂiximab
Fig. 2 Case 2 after missing two doses of inﬂiximab and
experienced a ﬂare of the cutaneous disease
Table 1 continued
Case 1 Case 2 Case 3
Inﬂiximab dose,
duration
5 mg/kg on weeks 0, 2, and 6,
then every 8 weeks
6 months later: add
methotrexate 7.5 mg weekly
after tapering prednisone
6 months later increased
inﬂiximab to 5 mg/kg and
7.5 mg/kg every 7 weeks
9 months later increased
inﬂiximab to 10 mg/kg every
5 weeks
7.5 mg/kg on weeks 0, 2, and 6,
then every 8 weeks
7.5 mg/kg on weeks 0, 2, and 6,
then every 8 weeks
4 years later tapered to 5 mg/kg
every 16 weeks





3 years 5 months 4 years
Treatments at
the time of last
follow-up
Inﬂiximab (10 mg/kg every
5 weeks)
Methotrexate (7.5 mg weekly)
Prednisone (2.5 mg/day every
other day)
Inﬂiximab (7.5 mg/kg every
8 weeks)
Discontinued inﬂiximab
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The patient’s lesions have since maintained
improvement with infliximab 7.5 mg/kg every
8 weeks (Fig. 2; Table 1).
Case 3
A 48-year-old African American woman was first
seen in the authors’ clinic in 2001 for
management of cutaneous sarcoidosis lesions.
The patient was diagnosed with cutaneous
sarcoidosis by biopsy of the preauricular area
in 1996. The patient was originally treated with
hydroxychloroquine and prednisone, but these
medications were discontinued due to side
effects. The patient was subsequently started
on methotrexate 15 mg/week and minocycline
100 mg twice a day. Methotrexate was increased
to 22.5 mg/week, prednisone was increased
to 40 mg/day, and hydroxychloroquine
250 mg/day was initiated. Because of side
effects from prednisone and methotrexate,
these medications were discontinued. The
patient was then lost to follow-up for
approximately 2 years. In May 2004, the
patient’s lesions flared, and thalidomide
100 mg/day was initiated with prednisone
20 mg/day and topical corticosteroids. As a
result of peripheral neuropathy, thalidomide
was discontinued after 2 months of treatment.
Infliximab 7.5 mg/kg at weeks 0, 2, and 6, and
every 8 weeks thereafter was started in August
2004. Figure 3 shows the lesions on the patient’s
upper extremities were significantly flattened
compared with initial presentation.
The patient’s lesions slowly improved with
no new lesions manifesting; Fig. 4 shows the
lesions on the patient’s upper extremities are
dramatically flattened compared with initial
presentation. Infliximab was tapered in
October 2008 to 5 mg/kg every 12 weeks and
was discontinued in November 2011. The
patient has currently not developed any new
lesions (Table 1).
DISCUSSION
Sarcoidosis is a multisystemic non-caseating
granulomatous disease of unknown origin that
is driven by T-helper type 1 immune responses
[27]. Cutaneous manifestations occur in 25–35%
ofcases and may present at the onsetof the disease
process [28–31]. Diagnosis is usually made by
clinical suspicion in conjunction with biopsy and
the exclusion of other conditions [32]. The
clinical history and prognosis of sarcoidosis is
variable. In cutaneous sarcoidosis, there are no
definite guidelines for systemic therapy, but
progressive, widespread, and disfiguring lesions
should certainly be treated [33].
Fig. 3 The clinical manifestation of case 3, 2 years after
initiating inﬂiximab
Fig. 4 The clinical manifestations of case 3, 6 years after
initiating inﬂiximab
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Systemic and topical corticosteroids remain
the mainstay of treatment for various
manifestations of sarcoidosis, including
cutaneous sarcoidosis [33]. Unfortunately, the
long-term side effects make corticosteroids a
less than ideal long-term treatment option, and
some patients remain refractory to this
management strategy.
Tumor necrotic factor (TNF)-alpha is an
important proinflammatory cytokine involved
in the pathogenesis of sarcoidosis. Macrophages
of sarcoidosis patients have been implicated as
major releasers of TNF-alpha in sarcoidosis
[34, 35]. Higher serum TNF-alpha levels have
been shown not only in patients with slow
onset sarcoidosis compared with acute onset,
but levels have been shown to fluctuate in
correlation with disease activity [36–38]. In
addition, increased levels of TNF-alpha have
been correlated with a greater risk of disease
progression, relapse, and difficulty with
treatment [36].
As a result of evidence of TNF-alpha
involvement in the pathogenesis of sarcoidosis
[39, 40], alternative therapies for cutaneous
sarcoidosis such as the TNF-alpha antagonists
have been proposed [2, 3]. Reports on the
efficacy of TNF antagonists used for cutaneous
sarcoidosis are increasing, although at this time
this treatment modality remains off label by
the standards of the US Food and Drug
Administration. Although there have been no
comparative trials between the biologic agents
for sarcoidosis, infliximab is the most heavily
reported medication in the literature [6–11],
and overall has shown great promise in the
treatment of sarcoidosis patients refractory to
more conventional therapies [6, 7, 12, 26].
Favorable outcomes of infliximab therapy in
patients who have renal sarcoidosis [13],
vertebral sarcoidosis [14], joint sarcoidosis [15],
optic neuropathy [16], pulmonary sarcoidosis
[6, 17], retinal vasculitis [18], cutaneous
sarcoidosis [3–5, 22], neurosarcoidosis [19],
and cardiac sarcoidosis [20] have also been
reported.
For sarcoidosis patients reported in the
literature, the usual dose of infliximab has
been 3–10 mg/kg per dose at 0, 2, and 6 weeks,
followed by every 8 weeks for maintenance [25,
34]. If patients respond insufficiently to 5 mg/kg,
reducing the treatment interval has been
shown to lead to higher trough levels than
increasing the dose [25]. A randomized, double-
blind, placebo controlled study on the efficacy
of infliximab in 36 sarcoidosis patients with
cutaneous and pulmonary involvement used
a 6-week maintenance regimen. After 24 weeks
of treatment, patients overall showed
improvement in cutaneous findings compared
with placebo, although this was not statistically
significant (P = 0.09) [12]. In addition, a
retrospective review of lupus pernio
(13 courses of treatment with infliximab in
nine patients) reported the success of a 6-week
maintenance regimen, which was statistically
more efficacious than corticosteroids used
with and without other non-steroid
immunosuppressive agents (P = 0.0015) [5]. All
three patients in the current case study were
able to control their cutaneous sarcoidosis,
although doses had to be tailored to the
severity and variably refractory nature of their
diseases. However, it should be noted by the
prescribing physician that increased doses of
immunosuppression can of course lead to an
increased tendency toward infection, and can
also be associated with demyelination and
worsening of multiple sclerosis lesions [41].
Increasing doses of infliximab should not be
given lightly.
While TNF inhibitors have been shown to be
of benefit in treating sarcoidosis, it is of some
interest that a few cases have been reported
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wherein patients developed sarcoidosis while
undergoing treatment with anti-TNF therapy.
In the largest reported series of sarcoid-like
granulomas developing during TNF inhibitor
therapy [42], three of 10 patients treated with
infliximab for ankylosing spondylitis developed
pulmonary sarcoidosis 14–51 months after the
initiation of treatment. All three patients
improved within 6 months of discontinuation
[42]. Other case reports of infliximab-treated
patients include one patient with ankylosing
spondylitis who developed pulmonary
sarcoidosis after 5 years of therapy [43], and
patients with psoriatic arthritis who developed
pulmonary sarcoidosis [44] and cutaneous
sarcoidosis [45]. The mechanisms of sarcoidosis
development during anti-TNF-alpha therapy are
unclear.
In an article by Saleh et al. [21], the following
were offered as indications to initiate treatment
with infliximab for refractory sarcoidosis:
• unsuccessful treatment with systemic
corticosteroids;
• intolerant to systemic steroids side effects;
• unsuccessful treatment or intolerance to
other systemic therapies;
• requirement for additional systemic therapy
but intolerant to alternative agents.
CONCLUSION
In summary, the authors report three cases of
patients with refractory sarcoidosis successfully
treated with infliximab. Their clinical outcomes
were good, sustained, and there was no
associated morbidity from the medication.
Definite indications, dosage, interval, and
duration of treatment for cutaneous sarcoidosis
are not firmly established, although altering the
dose and schedule of infusions can be useful in
bringing the disease under optimal control.
Larger randomized controlled trials are
warranted to validate the efficacy of infliximab
in patients with cutaneous sarcoidosis.
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